dPCR Lung Cancer Mutation Screening Kit
The Atila digital PCR (dPCR) lung cancer mutation screening kit identifies 108 possible mutation sites in four groups in a rapid and cost-effective manner.
Each kit includes 100 tests.
CE-IVD Certified. Meets EU standards for safety and performance.
dPCR Lung Cancer Mutation Screening Kit
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It has become evident that somatic mutations in many different genes have been found in lung cancer cells, including EGFR, KRAS, HER2, MET and BRAF, etc.
The status of genetic mutations can influence response to targeted therapy. Therefore, testing for these mutations and tailoring therapy accordingly are widely accepted as standard practice.
Cancer is a genetic disease with uncontrolled growth of abnormal cells. Some types of cancer are frequently associated with specific genetic mutations. Those mutations provide the biomarkers that allow more specific cancer treatments, known as targeted therapy.
Targeted therapy is a newer type of cancer treatment that offers patients the opportunity to use a drug that has a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. Therefore, it is a critical step towards targeted therapy by identifying the cancer mutations with a precise and sensitive method.
Features Include
Technical Specs
Workflow Overview for the dPCR Lung Cancer Mutation Screening Kit
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
DNA Extraction
PCR Reaction Assembly
Digital PCR
